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Abstract 16 
Animal African trypanosomiasis (AAT), caused by Trypanosoma congolense and 17 
Trypanosoma vivax, remains one of the most important livestock diseases in sub-18 
Saharan Africa, particularly affecting cattle. Despite this, our detailed knowledge 19 
largely stems from the human pathogen T. brucei and mouse experimental 20 
models. In the post-genomic era the genotypic and phenotypic differences 21 
between the AAT-relevant species of parasite or host and their ‘model organism’ 22 
counterparts are increasingly apparent. We aim to outline the timeliness and 23 
advantages of increasing the research focus on both the clinically relevant 24 
parasite and host species – improved tools and resources for both have been 25 
developed in recent years. We propose that this shift of emphasis will improve 26 
our ability to efficiently develop tools to combat AAT. 27 
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 2 
Animal African trypanosomiasis – Time to switch models to improve 29 
translation of basic research to potential interventions 30 
While human African trypanosomiasis (HAT) has reached the point where 31 
eradication is being discussed[1, 2], animal African trypanosomiasis (AAT) 32 
remains one of the most significant infectious disease threats to sub-Saharan 33 
livestock [3](Figure 1). Although recently there has been a slowly increasing 34 
effort to re-focus research on the main causative agents of AAT, Trypanosoma 35 
congolense and Trypanosoma vivax, our specific knowledge of the biology of 36 
these pathogens is dramatically outweighed by that for Trypanosoma brucei, 37 
variants of which cause HAT. Additionally, information on the host response, 38 
particularly immunological processes, to these two AAT pathogens in the 39 
economically and clinically relevant host – cattle – is scanty compared to the data 40 
generated using mouse models (there is a lack of data overall relating to T. vivax 41 
as most T. vivax strains do not grow in mice).  42 
In this article we outline the timeliness and benefits of increasing the research 43 
emphasis on both the clinically relevant parasites and host species – recent 44 
research developments have resulted in significantly improved tools and 45 
resources. We contend that an increased emphasis on furthering our 46 
understanding through the use of experimental models that incorporate both T. 47 
congolense, T. vivax and the bovine host will result in more efficient development 48 
of useful tools to combat AAT. 49 
 50 
AAT – one disease, multiple causative agents 51 
AAT is often treated as a single ‘disease’ but one of several factors in the 52 
variation in clinical presentation is that AAT is caused by multiple species and 53 
strains of trypanosomes, and often mixed infections. While the most 54 
economically important are T. congolense and T. vivax, T. b. evansi is a significant 55 
pathogen in cattle, and T. brucei s.l. is found in cattle, although it probably has a 56 
minor role in pathogenesis. Additionally, within the parasite species, genetic 57 
variation results in different clinical outcomes and relevance to disease in cattle, 58 
exemplified by greater pathogenicity of T. b. evansi compared with T. b. brucei, 59 
and of T. congolense Savannah compared with T. congolense Forest or Kilifi 60 
(reviewed in [3, 4]). Indeed, there is a requirement for furthering our 61 
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understanding of how this complex of species and strains affects AAT disease 62 
spectrum and epidemiology - an improved molecular systematics, particularly of 63 
T. congolense and T. vivax, would greatly help to resolve this. While classically 64 
thought of as solely an African disease, T. b evansi and T. vivax have adapted to 65 
mechanical transmission and by this means have spread beyond the tsetse 66 
transmission zone in sub-Saharan Africa to become established pathogens 67 
affecting the livestock industries of Asia (T. b. evansi) and South America (T. vivax 68 
and T. b. evansi)[5, 6].  69 
 70 
Antigenic variation and drug uptake are examples of key differences 71 
between trypanosome species. 72 
The importance of species-specific parasite knowledge is highlighted by recent 73 
examples where fundamental differences have been identified between the three 74 
African trypanosome species that indicate significant phenotype differences in 75 
traits highly relevant to clinical progression and/or control options. Insight has 76 
been accelerated by the successful sequencing of the genomes of T. congolense 77 
and T. vivax (www.tritrypdb.org [7]), and we highlight below two examples 78 
where comparative analyses between these species and T. brucei [8, 9] has 79 
indicated some stark, and perhaps unexpected, differences.   80 
 81 
Antigenic variation  82 
African trypanosomes are a paradigmal organism for antigenic variation [10, 11]. 83 
Trypanosomes express this phenotype through the variant surface glycoprotein 84 
(VSG), which forms a surface monolayer of homodimers. Antigenic variation 85 
works through selective expression of a single copy of antigen, and the active and 86 
regular changing of this protein to stay one step ahead of the host adaptive 87 
immune response, for which the VSG is highly immunodominant. Trypanosomes 88 
have an incredibly elaborate system resulting in an enormous repertoire of 89 
antigens (approximately 2000 VSG genes in T. brucei [8, 12-14] – dwarfing that 90 
of similar pathogens such as Plasmodium falciparum that also use antigenic 91 
variation [15]). However, almost all of our knowledge on this system was until 92 
recently obtained in T. brucei. The generation of genome sequence and 93 
comparative analysis of T. congolense and T. vivax, and comparison of the VSG 94 
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repertoires of these species and T. brucei, has revealed some surprising and 95 
significant differences [8]. 96 
T. brucei VSGs comprise two types, VSGa and VSGb, as defined by N-terminal 97 
domain types (the domains whose epitopes are exposed to the host immune 98 
response)[13, 16, 17]. In contrast, T. congolense contains no a-type VSGs but only 99 
bVSGs, which additionally form two sub-families. Furthermore, in T. congolense 100 
the bVSG family was further resolved into 15-20 types based on differences in 101 
the C-terminal domains (which tether the VSG to the surface membrane and 102 
confer structural properties to the VSG protein). All T. brucei VSGs share a 103 
relatively uniform C-terminal domain that is crucial to the mechanism of genetic 104 
recombination between T. brucei VSGs; that the situation in T. congolense differs 105 
so markedly suggests a different mechanism. Therefore, these data indicate 106 
significantly greater structural diversity in VSGs in T. congolense than T. brucei. T. 107 
vivax, which is the most basal branching trypanosome lineage known, was found 108 
to possess some VSG types analogous to VSG a and b, but also two further types 109 
that did not have orthologues in T. congolense or T. brucei, suggesting even 110 
greater structural diversity than in these two pathogens (however, the identity 111 
of these additional types as VSGs requires confirmation). Additionally, 112 
phylogenetic analysis of the VSG repertoires revealed evidence for a range of 113 
contribution of within-family recombination in generating VSG diversity across 114 
the different species, with T. brucei displaying evidence of frequent 115 
recombination, T. vivax relatively little, and T. congolense being intermediate. 116 
These differences are likely to reflect mechanistic differences in how the species 117 
achieve the phenotype of antigenic variation by changing the identity and 118 
sequence of the expressed VSG, and importantly, underline that they are very 119 
distinct organisms. This may be relevant to potential development of tools, as 120 
many of the inferences with respect to antigenic variation and barriers to, for 121 
example, vaccine development, are entirely founded upon our knowledge of T. 122 
brucei. It has been known for some time that the VSG monolayer in T. vivax is less 123 
dense than the VSG coat in T. brucei (as indicated by electron micrographs [18]), 124 
and transcriptomic studies have demonstrated that VSG expression in T. vivax 125 
accounts for a significantly smaller proportion of total transcripts than in T. 126 
brucei [19, 20]. Therefore, the role the VSG barrier plays in shielding invariant 127 
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antigens (which theoretically could be more conducive to antibody/vaccine 128 
targeting) has not been explored in the different species and in T. vivax in 129 
particular (several T. vivax-unique non-VSG protein families have been identified 130 
that are predicted to be surface-expressed [19]). Indeed, this canonical notion of 131 
the physical VSG barrier in T. brucei has been questioned in a recent detailed 132 
review [21], highlighting that even in T. brucei much dogma remains to be 133 
challenged. 134 
 135 
Drug resistance 136 
A further example of genetic differences between trypanosome species relating 137 
to phenotypes of fundamental importance for disease progression and control is 138 
that of transporters of relevance for chemotherapy. Pentamidine and diminazene 139 
aceturate are two diamidine drugs used for treating HAT and AAT, respectively. 140 
In T. brucei, these drugs are transported primarily through the T. brucei P2 141 
adenosine transporter 1 (TbAT1 [22]). Diminazene has been the most widely 142 
used AAT trypanocide over decades, and as a result resistance is reported [23-143 
25]. Resistant strains of T. brucei fail to take up the drug as a result of mutations 144 
in TbAT1 [22, 26]. However, when the genome of T. congolense was analysed, the 145 
putative orthologue of TbAT1 was shown to not be so through both genomic and 146 
functional analysis [27] – indeed there is no detectable orthologue in the T. 147 
congolense genome. Therefore, the main route of diamidine drug uptake, and 148 
resistance, must be different in T. congolense (and probably in T. vivax, given 149 
there is also no clear TbAT1 orthologue in the current T. vivax genome assembly 150 
– see www.tritrypdb.org). These are fundamental differences that will relate 151 
directly to drug development initiatives in terms of identifying potential cross-152 
resistance with existing drugs and attempts to predictively identify drug 153 
resistance markers by generating resistant lines in vitro.  154 
 155 
These examples highlight the power of genomic information to fast track our 156 
understanding of similarities and differences between trypanosome species, but 157 
also underline that T. brucei often does not represent a model for T. congolense 158 
or T. vivax. Although we are in the early stages of defining functional relevance of 159 
between-species differences, we are entering an era where genomic tools and 160 
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resources are available [8, 9, 19], culture of relevant life cycle stages has been 161 
reported and, importantly, transfection systems for both organisms are available 162 
[28, 29]. Therefore, many of the barriers that previously existed to working with 163 
these trypanosome species have been removed or at least minimised. We can 164 
now increase our knowledge in the clinically relevant species, which should lead 165 
to more successful intervention (e.g. drug) development to combat AAT. For 166 
example, information gained in studies involving T. congolense and T. vivax 167 
regarding drug uptake and mechanisms of action, markers of resistance, and 168 
cross-resistance to existing compounds, assists drug candidate selection and 169 
may extend the useful lifetime of new drugs. 170 
 171 
What about the bovine host? 172 
The bovine immune response to trypanosomes is relatively poorly studied, 173 
particularly in light of the growing repertoire of tools and reagents that have 174 
been developed (see e.g. [30] and Table 1) in recent years. Additionally, several 175 
aspects of the bovine immune response have been described recently that are 176 
either unique or are significantly different to their human or murine 177 
counterparts (e.g. non-conventional T lymphocyte subsets with unique functions, 178 
significantly expanded natural killer (NK) cell receptor families, and ‘ultralong’ 179 
antibody CDR3 domains [31-35]). Thus, any potential influence of aspects such 180 
as these on trypanosome infections clearly cannot be accurately measured or 181 
tested in model organisms such as mice. As well as the continuing development 182 
of the repertoire of conventional resources and reagents, and similar to the 183 
situation with trypanosomes, we are clearly very much in the post-genomic era 184 
for the bovine host (Bos taurus and Bos indicus), resulting in both the uncovering 185 
of key differences between cattle and other species, as well as generation of 186 
polyomic datasets that serve as invaluable resources for analysing the bovine 187 
immune response [36-38]. It is increasingly clear that gene editing technologies 188 
are much more readily applicable to large animals than was previously possible 189 
[39], meaning that both in terms of feasibility and cost the alteration of genotype 190 
to assess phenotype is now a real option. Much of the work analysing the bovine 191 
immune response to trypanosomes was undertaken some time ago (reviewed in 192 
[40, 41]). More recently, there have been key insights from bovine genetics 193 
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studies (that have not explicitly incorporated immunology) and mouse studies, 194 
and we highlight two examples below where application of immunological 195 
analysis in cattle may progress our understanding of key phenotypes in AAT. 196 
 197 
Trypanotolerance 198 
One aspect that has received much attention is the role of host genetics - some 199 
cattle breeds remain infected but do not display the clinical disease of 200 
susceptible breeds (‘trypanotolerance’ [42]). This has been exploited using 201 
classical genetics to identify genes and potential pathways involved in successful 202 
control of trypanosome infections in the bovine host [43, 44]. While immune 203 
response parameters were not explicitly measured phenotypes in these studies, 204 
the regions linked to measured phenotypes (parasitaemia, body weight and 205 
packed cell volume) contain candidate genes (the alleles of which are 206 
responsible for conferring trypanotolerance) whose putative function is in 207 
several cases linked to the immune response. In particular, these data indicate 208 
that a NK cell receptor gene (Cd244), a gene in the Toll-like receptor pathway 209 
(TICAM1) and genes such as MAPK whose effect may influence several immune 210 
response pathways, are implicated in controlling trypanotolerance.  However, 211 
how the products of these genes and pathways influence the bovine immune 212 
response and functionally reduce clinical symptoms has not been addressed. To 213 
fully validate the involvement of such pathways and genes, it will be essential to 214 
analyse immunological function to understand the role that such alleles have in 215 
the interaction with trypanosomes.  216 
Much of current knowledge of immune response to trypanosomes has stemmed 217 
from the mouse model. This undoubtedly led to significant advances in our 218 
understanding, and helped to highlight many of the unique features of 219 
trypanosome infections and their interaction with the mammalian immune 220 
response. This has included work on the hierarchy of genetic susceptibility to 221 
trypanosome infections in mice (in parallel with the bovine trypanotolerance 222 
data) that has led to identification of candidate loci and pathways responsible for 223 
controlling trypanosome infections in mice [45, 46]. The comparison with cattle 224 
trypanotolerance is instructive, as the phenotypes used to assess genotype 225 
linkage in the mouse model were necessarily different (survival time in mice 226 
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versus multiple pathogenesis phenotypes in cattle) and there was relatively little 227 
overlap in identified genes and pathways, probably due to both fundamental 228 
organismal differences and differing measured phenotypes. However, there were 229 
some interesting overlaps - in particular Cd244 and the NK cell pathway were 230 
implicated in both models [44, 46]. Given the identification of a common process 231 
despite the differences in protocol and organism, it is tempting to conclude that 232 
NK cells in cattle are worthy of specific attention regarding their role in 233 
controlling trypanosome infections. The increasing availability of tools and 234 
knowledge [35] to dissect bovine NK cells and their responses will be central to 235 
such studies. Humans and mice express distinct NK cell receptor families (KIR 236 
and Ly49 (KLRA)) that have functional similarities but are encoded by distinct 237 
gene complexes within the genome [47]. Outside of humans and other simian 238 
primates, cattle (B. taurus & B. indicus) are the only species to have an expanded 239 
polymorphic KIR gene family [48] and a polymorphic Ly49 gene [49].  240 
 241 
Immunosuppression 242 
A cardinal sign of trypanosomiasis is immunosuppression, and this phenotype is 243 
an example where the mouse experimental model has produced interesting and 244 
novel insights. Recent studies have demonstrated in the murine model that this 245 
is through parasite-driven B cell apoptosis and loss of immunological memory 246 
[50-53]. Although the precise mechanism and the parasite ligand that mediates it 247 
have not been identified, this phenotype is well defined in mice – the initial work 248 
used T. brucei but subsequent studies demonstrated a similar effect in T. 249 
congolense infected mice [54]. It would be interesting and timely to determine if 250 
this phenotype occurs in cattle to a similar extent via the same or related 251 
mechanisms - there is evidence that specific memory loss occurs in infected 252 
cattle [55] but perhaps not to the same degree as in mice. In cattle pre-253 
challenged with irradiated T. brucei, then infected with T. congolense and 254 
subsequently challenged with the same irradiated T. brucei, 3 of 5 cattle showed 255 
reduced recall response to the T. brucei inoculation [55]. Equally pertinent would 256 
be to compare whether this phenotype is consistent or varies depending on 257 
parasite species in cattle.  258 
 259 
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The importance and relevance of understanding the bovine immune response to 260 
trypanosomes is clear. Understanding the ability of the bovine host to control the 261 
parasite has direct implications for potential vaccine development strategies and 262 
other anti-disease interventions. The authors wish to emphasise that the 263 
purpose of this article is not to minimise what has been achieved or the general 264 
utility of mouse models in advancing our understanding (see [56, 57]), but given 265 
recent progress in tools and resources we aim to highlight that more emphasis 266 
on understanding the bovine model is timely and will reap dividends for 267 
enhancing our understanding and control of AAT. At some point during studies 268 
of a livestock disease, findings in the murine model need to be validated and 269 
translated to the relevant host – our ability to do this meaningfully is now 270 
greater than ever. 271 
 272 
Concluding Remarks and Future Directions 273 
The genetic and phenotypic differences between T. brucei, T. vivax and T. 274 
congolense compel more research focussed on understanding the between-275 
species differences that are pertinent to phenotypes relevant to potential 276 
strategies for controlling AAT. Additionally, given recent findings highlighting 277 
unique features of bovine immune responses, our understanding of these 278 
responses to trypanosomes requires updating, the results of which will 279 
undoubtedly feed into defining key aspects of AAT and its control. Moreover, the 280 
development of post-genomic resources and tools for both cattle and livestock 281 
trypanosome species mean that many barriers to working with these organisms 282 
are removed (Figure 2).   283 
However, it cannot be ignored that there are significant challenges involved in 284 
moving to the bovine model and limitations that need to be appreciated (Table 285 
1); these largely centre on cost but also the availability of appropriate facilities to 286 
run in vivo infections on the requisite scale is relatively limited.  This places an 287 
onus on funders to understand these challenges and to provide the appropriate 288 
support for work in cattle – ultimately there is no short cut to generating 289 
meaningful progress in the clinically relevant host.   290 
We suggest that research priorities should be directed at applying the tools and 291 
resources described in this article to some of the key gaps in our knowledge 292 
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relating to both the trypanosome species and the bovine response to them (see 293 
Outstanding Questions Box); namely (a) exploiting well characterised 294 
phenotypes in T. brucei as a platform to analyse key differences in T. congolense 295 
and T. vivax (e.g. antigenic variation, drug transport/resistance), (b) assessing 296 
the translation of key phenotypes in the murine model to the bovine host (e.g. B 297 
cell apoptosis and immunosuppression), and (c) characterising the role of 298 
unique features of the bovine immune response in trypanosomiasis and their 299 
interplay with T. congolense and T. vivax. Advancing our knowledge in these 300 
areas will significantly enhance our understanding of trypanosome infection 301 
biology in the cow. 302 
Finally, the identification of a holistic, and realistic, approach to controlling AAT 303 
will ideally come from integrated studies - using both AAT causative agents and 304 
cattle will be more informative in identifying both host and pathogen factors 305 
specific to AAT that are amenable to intervention (Figure 2). Therefore, it is 306 
timely to increase the research focus on clinically relevant host and trypanosome 307 
species for AAT. 308 
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TABLE 1.  Comparative attributes and challenges of working with either mice or 596 
cattle in Trypanosomiasis studies of pathogenesis, pathophysiology and efficacy 597 
(e.g. pharmaceutical or vaccine candidates). 598 
 599 
  600 
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Figure Legends 601 
 602 
Figure 1. Distribution of animal African trypanosomiasis caused by 603 
Trypanosoma congolense and Trypanosoma vivax.  604 
 605 
Figure 2. Illustrative pipeline for the development of tools against animal 606 
African trypanosomiasis (AAT) using an integrated host-parasite approach. 607 
Solid boxes represent current state of knowledge; dashed boxes represent future 608 
progress. With the aid of genome sequences key species-specific differences have 609 
been identified for both the bovine host and livestock trypanosome species 610 
(examples are illustrated in the green and blue boxes, respectively). The 611 
exploitation of such findings and increasing the emphasis on research that uses 612 
the clinically relevant species of host and parasite will maximise the potential for 613 
future tools against AAT – ideally in integrated studies where both parasite and 614 
host factors can be identified. 615 
Parameter Mice Cattle 
Cost per animal Low High 
Ability to scale up numbers 
& appropriately power 
experiments 
Easy and low cost Difficult and expensive 
(Limited facilities worldwide that 
can incorporate large numbers of 
infected animals) 
Between animal variability Low – multiple inbred lines 
available 
High –animals are outbred 
(Also many phenotypes show 
variation between breeds) 
Ability to genetically 
manipulate 
(e.g. gene knockout) 
Straightforward – many 
gene knockout lines 
available. 
Currently difficult but 
prospects improving 
(e.g. Crispr/Cas9 approaches, but 
high costs for maintaining lines, 
long generation time) 
Reference genome quality Very good  
(Genomes of multiple strains 
available) 
Satisfactory 
( B. taurus & B. indicus genomes 
available, annotation patchy) 
Predictability of results for 
use in cattle in field 
Low 
(Useful for basic 
pathophysiology/immunobiology 
proof of principle and drug 
candidate selection after in vitro 
evaluation) 
High 
 Research tools Many                                           
(Readily available, low cost) 
Fewer but rapidly 
increasing  
(cellular and molecular tools, 
reagents & techniques – see [30]) 
Reagent or Active 
substance requirement: 
Quantity & cost 
Small 
(e.g. <1 mg) 
Large 
(e.g. for pharmaceutical, 10-20 g 
per parasite species) 
Animal facilities Readily available, low cost Containment and fly-proof 
facilities usually required  
(Few and expensive; may require 
endemic country e.g. T. vivax) 
Trypanosome isolates Mainly laboratory strains 
(Limited and only one, old strain 
of T. vivax –Y486) 
All can be used 
 (Including recent, drug resistant, 
field isolates) 
Typical efficacy study 
duration 
60 days 100 days 
Drug candidate route of 
administration 
S/C or I/P As intended for final 
product 
(e.g. S/C, I/M) 
Drug candidate 
formulation 
Usually simple 
(e.g. DMSO-based for small 
molecule) 
May require formulation 
development 
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Trends Box  
The T. congolense & T. vivax genomes revealed significant differences in key 
genes/gene families for relevant phenotypes compared to T. brucei.  
 
The variant surface glycoprotein (VSG - confers antigenic variation) repertoires 
indicate significant divergences in structural diversity and relative role of 
recombination in generating VSG diversity.  
 
T. congolense lacks an orthologue of the main diamidine transporter in T. brucei 
(TbAT1), meaning the route of drug uptake/resistance is different. 
 
Unique aspects of the bovine immune system have recently been identified, such 
as increased frequency of γδ T cell population and ultralong CDR3 domain 
antibodies.  
 
Natural Killer cells have been implicated in murine & bovine trypanosome 
susceptibility genetic studies. NK cells in cattle have been recently identified to 
have a uniquely expanded NK receptor repertoire. 
 
 
Trends Box
 1 
Outstanding Questions Box  1 
 Do the differences in T. brucei, T. congolense and T. vivax VSG repertoire 2 
reflect mechanistic differences in how they achieve the phenotype of 3 
antigenic variation? 4 
 Can these differences be exploited in either livestock species? 5 
 What are the key differences in transporter gene families of relevance to 6 
drug uptake/drug resistance? 7 
 Are there differences in the T. congolense and T. vivax genome that impact 8 
upon mechanism of action/mechanism of resistance for compounds in 9 
development? 10 
 What are the implications of differences in the T. congolense and T. vivax 11 
genome for integrated development of drugs that target both pathogens? 12 
 Do any of the unique features of the bovine immune response (e.g. 13 
frequency of γδ T cell population, ultralong CDR3 domain antibodies 14 
and expanded NK receptor families) play a role in the immune response 15 
to trypanosome infections? 16 
 Can any of the unique features of the bovine immune response be 17 
exploited to combat AAT? 18 
 How do the trypanotolerance genes exert their effect in the bovine 19 
immune system on trypanosome infections? 20 
 What is the role of cattle NK cells in trypanosome infections? 21 
 Does immunosuppression in cattle trypanosome infections occur via the 22 
same mechanism as identified in mice? 23 
 Does the same parasite ligand mediate this effect in mice and cattle, and is 24 
it conserved across T. brucei, T. congolense and T. vivax? 25 
 26 
Outstanding Questions
